Letter to the editor: no increased febrile neutropenia risk to cancer patients receiving lipegfilgrastim--correction of a systematic review and meta-analysis of randomized controlled trials with G-CSF

Support Care Cancer. 2016 May;24(5):1935-1937. doi: 10.1007/s00520-016-3116-3. Epub 2016 Feb 10.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Febrile Neutropenia / prevention & control*
  • Female
  • Filgrastim / therapeutic use*
  • Granulocyte Colony-Stimulating Factor / therapeutic use*
  • Humans
  • Lymphoma, Non-Hodgkin / drug therapy*
  • Primary Prevention*

Substances

  • Granulocyte Colony-Stimulating Factor
  • Filgrastim